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Abstract 
Changes in tumor metabolism may accompany disease progression and can occur following 
treatment, often before there are changes in tumor size.  We focus here on imaging methods 
that can be used to image various aspects of tumor metabolism, with an emphasis on methods 
that can be used for tumor grading, assessing disease progression and monitoring treatment 
response. 
 
Introduction 
Reprogramming of metabolism is a recognized hallmark of cancer (1), with altered fluxes in 
both anabolic and catabolic pathways.  Recent work has shown, for example, that some breast 
cancers are dependent upon increased serine biosynthesis (2) and that human lung tumors 
show high levels of both glycolysis and glucose oxidation (3).  Tumors often preferentially 
reduce pyruvate to lactate, rather than oxidize it in the tricarboxylic acid (TCA) cycle.  This 
failure to oxidize pyruvate, even in the presence of oxygen (the “Warburg Effect”), is not 
because mitochondria in cancer cells are necessarily dysfunctional, but rather because flux of 
pyruvate carbon into the TCA cycle is down regulated (4).  A major function of the TCA 
cycle in tumors is to generate building blocks for macromolecular biosynthesis, such as 
acetyl-CoA for fatty acid synthesis and amino acids for protein synthesis.  As in other tissues, 
tumors can utilize fuels other than glucose for energy generation, such as glutamine, fatty 
acids, ketone bodies and amino acids, with tumors adapting to nutrient availability and other 
micro-environmental factors (4).  Tumor cells can also exist in a metabolic symbiosis, 
whereby hypoxic tumor cells import glucose and export lactate, while nearby normoxic cells 
import and catabolize this lactate (5).  
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 Altered metabolic fluxes in cancer cells are intimately linked to control of redox state.  
NADPH, which maintains a major cellular anti-oxidant, glutathione, in a reduced state, can be 
generated by flux of glutamine carbon through the TCA cycle to malate, with the production 
of NAPDH in the reaction catalyzed by NADP+-dependent malic enzyme (ME, EC 1.1.1.40), 
and by flux of glucose carbon into the pentose phosphate pathway (PPP) (4).  Decreased 
glycolytic flux resulting from oxidation of a sensitive sulfhydryl residue in the pyruvate 
kinase (PK) isoform PKM2, promotes diversion of glucose carbon into the PPP (6).  Flux is 
also diverted into the PPP by TP53-induced glycolysis and apoptosis regulator (TIGAR), 
which possesses fructose 2,6-bisphosphatase activity, and re-routes glycolytic flux into the 
PPP by decreasing the amount of fructose 2,6-bisphosphate, a potent allosteric activator of the 
glycolytic enzyme phosphofructokinase 1 (PFK1) (7).  Flux of serine and glycine carbon 
through the tetrahydrofolate (THF) pathway also generates NADPH (2).  Increased uptake of 
glucose and glutamine by cancer cells drives the hexosamine pathway, which yields 
metabolites involved in protein and lipid glycosylation.  Increased O-glycosylation of proteins 
with N-acetylglucosamine promotes cancer cell metabolic reprogramming and cell survival 
and sialylation of cell-surface carbohydrates is associated with increased metastasis (8). 
 
The differences in metabolism between tumors and normal tissues and the changes in tumor 
metabolism during disease progression and in response to treatment make metabolic imaging 
techniques important tools for detecting and grading tumors and for guiding therapy in 
individual patients (9) (see Figure 1 and Table 1).   
 
PET 
Positron Emission Tomography (PET) with the glucose analogue, 2-[
18
F]fluoro-2-deoxy-D-
glucose (FDG) is the most widely used metabolic imaging technique in the clinic for tumor 
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staging and assessment of treatment response (10).  FDG is trapped by phosphorylation in the 
reaction catalyzed by the first enzyme in the glycolytic pathway, hexokinase.  Many tumor 
cells overexpress the glucose transporters (GLUT) 1 and 3 and therefore take up large 
amounts of FDG.  However, FDG-PET suffers from a lack of specificity as increased glucose 
uptake also occurs in inflammation (11).  Moreover, sensitivity is low in tumors with a low 
glycolytic rate, such as prostate tumors, or where the tumors are located in a tissue with high 
glucose uptake, such as the brain (9).  The Royal College of Radiologist’s guidelines 
recommend that imaging tumor treatment response with FDG-PET should commence weeks 
to months after chemo- or radiotherapy (12), which hampers rapid assessment of a therapy’s 
effectiveness.  Recently, a PET tracer for imaging PKM2 expression has been described, 
11
C]DASA-23, which may be more useful for detecting the increased aerobic glycolytic 
activity of tumors than FDG.  The tracer showed clear delineation of implanted patient-
derived glioblastoma tumors in mouse brain (13).  [
18
F]-2-deoxy-2-fluoroarabinose has been 
developed as a potential marker of PPP flux, accumulating predominantly in the liver, where 
PPP flux is high (14).  Most cells take up fatty acids for oxidation and energy production and 
for biosynthesis of membrane components, but tumors are unusual in that they can derive 
fatty acids predominantly via de novo synthesis (15).  However, hypoxic and Ras transformed 
cells have been shown to bypass de novo lipogenesis by scavenging exogenous fatty acids 
(16).  PET measurements with 
11
C-acetate have been used to measure de novo fatty acid 
synthesis in a range of cancers (17).  
11
C-acetate trapped by acetyl-CoA synthetases may also 
be used for non-lipogenic pathways, such as acetylation of histones (18).  In prostate cancer it 
is unclear whether 
11
C-acetate PET adds more clinical information than measurements of 
prostate-specific antigen (PSA) levels in plasma (19). Glutamine metabolism in many cancers 
is reprogrammed by oncogenes such as MYC and RAS, redirecting glutamine into biosynthetic 
pathways to promote proliferation and redox homeostasis as well as fuelling the hexosamine 
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pathway (4).  The PET tracer, 
18
F-(2S,4R)4-fluoroglutamine
 
(
18
F-FGln) showed a high 
tumour-to-brain uptake ratio in glioblastoma-bearing mice as well as in glioblastoma patients 
with progressive disease (20), which was reduced following chemo- and radiotherapy in the 
mice.  As there is no uptake in models of neuro-inflammation or in mice with a compromised 
blood brain barrier this makes 
18
F-FGln a specific PET tracer for glutamine-addicted brain 
tumours. Although a wide range of PET tracers have been developed for interrogating other 
aspects of tumor metabolism, including uptake of other amino acids and tracers reporting on 
tissue redox state and pH (19, 21), few have translated into routine clinical practice (21).  
 A drawback of PET is that only tracer uptake can be assessed, although this may be 
related to underlying metabolism.  Information on true metabolic conversion requires blood 
sampling to obtain dynamic information on metabolite formation (21).  This is not a problem 
for magnetic resonance spectroscopy (MRS) since the spectrum can identify the observed 
molecule.  For example, glycolytic flux cannot be assessed from PET measurements of FDG 
uptake, which is rather an indication of glucose uptake than glycolytic flux to pyruvate and 
lactate.  In a study of canine tumors undergoing sequential imaging with hyperpolarized [1-
13
C]pyruvate and FDG PET there was not always concordance between FDG uptake and [1-
13
C]lactate labeling from hyperpolarized [1-
13
C]pyruvate (22).  An advantage of PET, 
however, is that very low concentrations of tracer can be used, which leaves the metabolism 
of the cell undisturbed.   
 
Magnetic resonance spectroscopy 
1
H MRS has been used clinically in the brain, where resonances from choline, lipids and N-
acetylaspartate (NAA) have been observed (23) and in the prostate, where resonances from 
citrate and choline predominate (24).  Metabolite ratios can help define malignant versus 
benign lesions in both brain and prostate, however it is questionable how useful these 
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metabolite signals are.  
1
H MRS data can help to identify regions for biopsy, but it is the 
histopathological findings rather than MR spectra that guide clinical decision making (25), 
and in prostate cancer MRS data adds little to multi-parametric magnetic resonance imaging 
(MRI) measurements (26).  However, some recently discovered 
1
H MRS biomarkers may be 
more useful.  The “oncometabolite”, 2-hydroxyglutarate (2HG), which results from a 
mutation in isocitrate dehydrogenase 1/2 (IDH1/2), can be detected in grade 2/3 gliomas by 
1
H MRS (27).  Although the use of 2HG levels to grade gliomas remains contentious (27), 
1
H 
MRS measurements of 2HG can also be used to monitor treatment response (28).  Glycine 
may provide another marker of brain tumor malignancy, as the ratio of glycine in tumor 
versus normal brain increases with glioma grade (29).  Germline mutations in the TCA cycle 
enzyme succinate dehydrogenase (SDH) can be found in certain renal cancers, 
phaeochromocytomas, gastrointestinal stromal tumors and paragangliomas.  The resulting 
accumulation of succinate, which can be observed in 
1
H spectra (30), may act as an 
“oncometabolite” by inhibiting hypoxia-inducible factor 1 (HIF-1) degradation (31).   
 
13
C MRS has been used in clinical studies of brain (32) and lung (3) tumors, where 
13
C-labeled substrates were infused prior to surgery and tumor samples were frozen 
immediately after resection and extracted for 
13
C MRS analysis. 
13
C resonances from 
glutamine, glutamate, aspartate, γ-aminobutyric acid (GABA) and NAA have been detected in 
human brain in vivo at high magnetic field (7T) following infusion of [2-
13
C]glucose (33).  
However, low spatial resolution and long acquisition times would make these 
13
C MRS 
measurements in vivo challenging to use in a routine clinical setting.  
31
P MRS was used in an early study of a human tumor in situ (34), however a lack of 
sensitivity has inhibited its use in clinical oncology.  The 
19
F nucleus is almost as sensitive as 
the proton to NMR detection and has the advantage that there is no background signal in 
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biological systems.  
19
F MRS has been used mainly for tracking labeled cells (35) and for 
detecting probes sensitive to various biologically relevant parameters, such as tumor hypoxia 
(36).  A recent advance is the use of combined PET/MR scanners (37).  For example, 
simultaneous diffusion-weighted MRI and PET measurements of 
18
F-FDG uptake in both pre-
clinical models and patients (38, 39) allowed metabolic effects to be distinguished from 
changes in cell viability. 
 
CEST 
Metabolites can be detected in MR images of tissue water by exploiting the chemical 
exchange saturation transfer (CEST) effect.  Resonances of labile metabolite protons that 
exchange with water are selectively saturated using long, low power r.f. pulses and the 
resulting decrease in the water signal is detected in a conventional MR image (40).   The 
technique has been used to detect glycogen in mouse liver (41), glucose (glucoCEST) in 
tumors, where the signal was shown to correlate with FDG-uptake (42), and lactate in a 
mouse model of lymphoma and in exercising skeletal muscle of healthy volunteers (43).  
However, in the case of glucoCEST, the contributions of intracellular glucose, glucose 
metabolites and glucose in the vasculature and interstitial space to the signal are currently 
unknown. 
 
Dynamic Nuclear Polarization 
Signal from injected 
13
C-labelled metabolites can be increased greatly (>10
4
x) by dissolution 
dynamic nuclear polarization (DNP) (44).  Carbon-13 labeled molecules are mixed with a 
stable radical and cooled to ~1 K in a high magnetic field.  At this temperature the electron 
spins in the radical are almost completely polarized.  Microwave irradiation at the resonance 
frequency of the electron spin transfers this polarization to the 
13
C nuclei.  Rapid dissolution 
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with superheated, pressurized buffer brings the 
13
C-labeled molecule to room temperature 
with substantial retention of the nuclear spin polarization.  The hyperpolarized 
13
C-labeled 
substrate can then be injected and the transient hyperpolarized signal, which in vivo can last 
for 2 – 3 minutes depending on the substrate, can be detected using 13C MRS or 13C magnetic 
resonance spectroscopic imaging (MRSI) (45).  More than 60 hyperpolarized molecules have 
been used in vitro and/or in animal models in vivo (46).  Hyperpolarized [1-
13
C]pyruvate, 
which in tumors exchanges the hyperpolarized 
13
C-label with the large endogenous lactate 
pool, has transitioned into the clinic.  In prostate cancer patients, hyperpolarized [1-
13
C]pyruvate allowed early detection of biopsy-proven tumor lesions that were unidentifiable 
by standard T2-weighted MRI (47).  Other metabolites, such as [1,4-
13
C2]fumarate (a marker 
of necrosis (48)) and [1-
13
C]dehydroascorbic acid (DHA, a marker of cellular redox state 
(49)) also show promise for clinical translation (50).  Hyperpolarized [U-
2
H, U-
13
C]glucose 
has been used to measure glycolytic flux in a tumor model in vivo, as well as flux into the 
pentose phosphate pathway (51).  Short-chain fatty acid metabolism can be investigated with 
hyperpolarized [1-
13
C]acetate and [1-
13
C]butyrate (52, 53), which resulted in observable 
labeling of acetylcarnitine in heart muscle.  Amino acids have so far shown little promise as 
hyperpolarized substrates, as their polarization lifetimes are too short to observe slow 
anabolic processes and even catabolic processes, such as the deamidation of glutamine, are 
too slow for MRSI (54).   
Hyperpolarized 
13
C-labeled serine and glycine could in principle be used to probe 
mitochondrial NADPH production via THF metabolism.  However, we have not observed 
metabolism of hyperpolarized 
13
C-labelled serine or glycine in EL4 murine lymphoma 
tumors, although small amounts of labeled bicarbonate were produced following injection of 
hyperpolarized [1-
13
C]glycine when data were acquired from over the whole abdomen 
(unpublished data).   
 9 
Cytosolic redox state can be assessed by measuring the concentrations of pyruvate and lactate, 
which are in near-equilibrium with NAD
+
 and NADH in the reaction catalyzed by lactate 
dehydrogenase (LDH).  Similarly mitochondrial redox state can be assessed from 
measurements of the near-equilibrium D-3-hydroxybutyrate/acetoacetate ratio (Figure 2a).  
Measurements of the hyperpolarized 
13
C-labeled lactate/pyruvate ratio in cells incubated with 
hyperpolarized glucose has been used to estimate the cytosolic NAD
+
/NADH ratio (55).  
However, in a rat Morris hepatocellular carcinoma model, administration of hyperpolarized 
[1,3-
13
C2]ethyl acetoacetate, which was rapidly hydrolyzed by intracellular esterases to 
produce [1,3-
13
C2]acetoacetate, resulted in no detectable production of labeled 
hydroxybutyrate (56).  Addition of hyperpolarized [1,3-
13
C2]acetoacetate to an EL4 murine 
lymphoma cell suspension showed exchange of hyperpolarized 
13
C label with co-injected 
unlabeled D-3-hydroxybutyrate, which appeared to be decreased in cells treated with the 
chemotherapeutic drug, etoposide [Figure 2 b, c].  This exchange was also observed in 
implanted EL4 murine lymphoma tumors, without co-injection of unlabeled D-3-
hydroxybutyrate.  Interestingly, D-3-hydroxybutyrate accumulates in some ovarian cancers 
(57).  In non tumor-bearing mice 
13
C label was also observed in acetyl-CoA in the liver/heart 
region following injection of hyperpolarized [1,3-
13
C2]acetoacetate [Figure 2 d].  Injection of 
DL-[1,3-
13
C2, 3-
2
H]-3-hydroxybutyric acid into non tumor-bearing mice resulted in detectable 
labeling of acetoacetate, pyruvate and bicarbonate, when signal was acquired from over the 
heart/liver region [Figure 2 e] (58).  
 
Current research in this area is focused on improving methods for fast imaging, analyzing 
kinetic data with [1-
13
C]pyruvate, and translating new substrates to the clinic (50).  Higher 
field-strength hyperpolarizers (59) and improved hyperpolarizer designs, with automated 
injection systems (60), will improve the levels of polarization and decrease the transfer time 
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from dissolution to injection.  Chemical derivatization to enhance tissue uptake (61) and 
prolongation of the polarization lifetime by deuteration (51) may allow the use of 
hyperpolarized substrates that so far have been limited by their slow cell uptake and/or short 
polarization lifetime.  The polarization process, which for a substrate such as [1-
13
C]pyruvate, 
can take over an hour, can be accelerated by first polarizing protons and then transferring this 
polarization to the 
13
C nuclei (62).  
 
Imaging cell surface glycosylation 
Cell surface glycosylation is important for cell-cell communication and adhesion, and hyper-
sialylation of cell surface glycans confers metastatic potential to a range of cancer cells (8).  
Glycosylation can be imaged using appropriately labeled probes that bind specific glycan 
moieties (63).  However, probe-based techniques give only a static picture of cell surface 
glycosylation, whereas metabolic labeling can give information on glycan turnover.  Cell 
surface glycans can be metabolically labeled with unnatural azido-sugars and the incorporated 
sugars can then be reacted in vivo with bioorthogonal probes (64), and visualized, for 
example, with fluorescence imaging (65), MRI (66) or radionuclide imaging (67).  Further 
development of sensitive radionuclide-labeled probes may allow high contrast real-time 
metabolic imaging of cancer glycosylation in vivo, which in the longer term has the potential 
to be translated to the clinic, where it could be used to image cancer progression and assess 
metastatic potential. 
 
The future of metabolic imaging in oncology 
There are some aspects of tumor metabolism for which there is as yet no imaging probe.  
Metabolic pathways important for both proliferation and resistance to oxidative stress, such as 
the PPP and the THF pathway, which produce NADPH, are underexplored imaging targets.  
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Enzymes involved in serine synthesis are emerging drug targets (68) and an imaging 
technique that could visualize serine/glycine metabolism and one-carbon transfer in vivo 
could improve our understanding of this branch of metabolism.  Hyperpolarized [U-
2
H, U-
13
C]glucose can be used to measure flux through the PPP (51) and may become relevant 
clinically with improved levels of polarization, potential further increases in polarization 
lifetime (by selective 
13
C labeling) and by employing routes of administration that allow 
faster delivery to the tissue of interest.  Hyperpolarized [1-
13
C]DHA as a marker of the 
capability of a tissue to resist oxidative stress (49) also has some potential to reveal new 
cancer biology.  
1
H MRS can be used to measure “oncometabolites”, such as 2HG (27) and 
succinate (30), and the development of hyperpolarized 
13
C-labeled substrates that could be 
used to explore the pathways leading to these oncometabolites could give more dynamic 
information on their metabolism (69).  Hyperpolarized DL-[1,3-
13
C2, 3-
2
H]-3-hydroxybutyric 
acid has shown some potential for exploring ketone body metabolism in vivo (58).  
Combining different imaging modalities such as PET/MR (37) with DNP (22) will increase 
the information content of the imaging examination, allowing more specific information to be 
obtained from the relatively few metabolic imaging tracers that have been approved for 
clinical use (70).  A newly emerging health concern in the clinic is the potential toxicity of 
gadolinium contrast media used in MRI (71).  In principle some of the roles of these contrast 
media could be replaced with hyperpolarized 
13
C-labeled cell substrates, for example 
hyperpolarized 
13
C urea, which has been used to assess tissue perfusion (72).  The power of 
metabolic imaging with hyperpolarized 
13
C-labeled cell substrates is that it gives information 
on dynamic processes.  However, its weakness is that there is no information on the 
concentrations of the labeled substrates and therefore no quantitative information on flux 
(expressed, for example, as M s
-1
).  While measurements of changes in this apparent first 
order rate constant have been demonstrated to be sufficient to detect treatment response in lab 
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based studies, this will need to be examined carefully in clinical studies.  Nevertheless the 
technique has great clinical potential, not only for detecting disease, disease progression (73, 
74) and treatment response (75) in cancer, but also in other pathologies such as 
neurodegenerative disorders and inflammation (50).    
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Figure legends 
Figure 1 Clinical imaging of cancer metabolism.  Many cancer cells metabolize glucose 
preferentially to lactate, even in the presence of oxygen (“Warburg effect”).  Glucose is taken 
up on the glucose transporters (GLUT), while pyruvate and lactate enter cells through the 
monocarboxylate transporters (MCT).  The pentose phosphate pathway (PPP) is linked to 
glycolysis via glucose 6-phosphate (G6P), which is oxidized by glucose 6-phosphate 
dehydrogenase (G6PDH).  Flux into the oxidative arm of the PPP is promoted by TP53-
induced glycolysis and apoptosis regulator (TIGAR).  Serine and glycine can be produced 
from 3-phosphoglycerate (3PG) and both amino acids can fuel the tetrahydrofolate (THF) 
pathway.  Glutamine is deamidated by glutaminase (GLS), which can yield NADPH via 
NADP+-dependent malic enzyme (ME, EC 1.1.1.40) activity.  NADPH generated from the 
oxidative PPP, ME flux and the THF pathway is used for lipid biosynthesis and redox balance 
while intermediates from the non-oxidative PPP and the THF pathway are used for nucleic 
acid synthesis.  Mutant isocitrate dehydrogenase (IDH) in the TCA cycle generates the 
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“oncometabolite” 2-hydroxyglutarate (2HG).  IDH1 in the cytosol is mutated in most grade 
II/III gliomas whereas IDH2 in the mitochondria is less commonly mutated.  The hexosamine 
pathway branches off from glycolysis at G6P and produces substrates for cell surface 
glycosylation.  Imaging agents that are used clinically and explore some of the above 
mentioned metabolic features of tumors are shown in: black and yellow (positron emission 
tomography tracers), green (hyperpolarized substrates) and blue (metabolites detectable by 
1
H 
MRS).  Abbreviations: 
18
F-FDG, 2-[
18
F]fluoro-2-deoxy-D-glucose; 
18
F-FGln, 
18
F-(2S,4R)4-
fluoroglutamine; 6PG, 6-phosphogluconate; 6PGDH, 6-phosphogluconate dehydrogenase; 
6PGL, 6-phosphogluconolactone; 6PGLase, 6-phosphogluconolactonase; αKG, α-
ketoglutarate; ALT, alanine aminotransferase; ChT, choline transporter DHAP, 
dihydroxyacetone phosphate; F1,6BP, fructose 1,6-bisphosphate; F2,6BP, fructose 2,6-
bisphosphate; FA, fatty acid; G3P, glyceraldehyde 3-phosphate; LDH, lactate dehydrogenase; 
OAA, oxaloacetate; PEP, phosphoenolpyruvate; PFK1/2, phosphofructokinase 1/2; Ru5P, 
ribulose 5-phosphate; SDH, succinate dehydrogenase; TPI, triosephosphate isomerase. 
 
Figure 2 Assessing ketone body metabolism with hyperpolarized 
13
C-labeled cell substrates.  
(a) Metabolism of the ketone bodies acetoacetate and D-3-hydroxybutyrate.  Abbreviations: 
AcAc, acetoacetate; BDH, D-3-hydroxybutyrate dehydrogenase; D-3-HB, D-3-
hydroxybutyrate; OAA, oxaloacetate; AcAcCoA, acetoacetyl CoA; ACOAS, acetyl-CoA 
synthetase; ACOAT, acetyl-CoA thiolase; ACYL, ATP-citrate lyase.  (b) Spectrum showing 
the resonances observed 30 s after injection of hyperpolarised [1,3-
13
C2]acetoacetate at a final 
concentration of 15 mM, into an EL4 murine lymphoma cell suspension (10
8
 cells).  
Unlabeled D-3-hydroxybutyrate was added in an equimolar amount.  There are resonances 
from C1 [1,3-
13
C2]acetoacetate at 177.3 ppm and D-3-[1-
13
C]hydroxybutyrate at 183.0 ppm 
(indicated by the arrow).  (c) Labeling of D-3-hydroxybutyrate decreased after the cells were 
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treated with etoposide for 16 h (unpublished data).  (d) Injection of hyperpolarized [1,3-
13
C2]acetoacetate in vivo.  The spectrum was obtained by summing the first 30 s of non-
localised spectra, where the surface coil was placed directly over the heart/liver region (58).  
The peak at ~212 ppm is C3 [1,3-
13
C2]acetoacetate.  The spectrum also shows a resonance at 
~204 ppm, which is most likely from [1-
13
C]acetyl-CoA.  (e) Representative spectrum 
obtained by summing the first 30 s of data acquired following administration of 0.2 mL of 
60 mM hyperpolarized DL-[1,3-
13
C2, 3-
2
H]-3-hydroxybutyric acid to a non-tumor bearing 
mouse via a tail vein catheter, where the surface coil was placed directly over the heart/liver 
region.  The observed resonances correspond to: 1) C1 DL-3-[1,3-
13
C2, 3-
2
H1]hydroxybutyrate (183.0 ppm); 2) [1-
13
C]acetoacetate (177.3 ppm); 3) [1-
13
C]pyruvate 
(172.8 ppm); 4) 
13
C bicarbonate (161.3 ppm) and 5) an unknown metabolite (144.9 ppm) 
(53). 
